$8.06
2.03% yesterday
Nasdaq, Oct 21, 10:00 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$8.06
+0.22 2.81% 1M
+0.66 8.92% 6M
-5.65 41.21% YTD
-14.48 64.24% 1Y
-11.51 58.81% 3Y
-5.96 42.51% 5Y
-32.65 80.20% 10Y
-2.69 25.02% 20Y
Nasdaq, Closing price Tue, Oct 21 2025
+0.16 2.03%

Key metrics

Basic
Market capitalization
$749.9m
Enterprise Value
$734.9m
Net debt
positive
Cash
$74.0m
Shares outstanding
93.0m
Valuation (TTM | estimate)
P/E
negative | 1,284.9
P/S
0.9 | 0.9
EV/Sales
0.9 | 0.9
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
68.2%
Return on Equity
-18.2%
ROCE
-16.1%
ROIC
-13.3%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$832.9m | $839.0m
EBITDA
$-17.9m | $29.2m
EBIT
$-76.6m | $5.3m
Net Income
$-395.1m | $580.0k
Free Cash Flow
$-47.5m
Growth (TTM | estimate)
Revenue
3.8% | 0.2%
EBITDA
57.8% | 208.9%
EBIT
25.3% | 106.1%
Net Income
-154.1% | 100.5%
Free Cash Flow
67.0%
Margin (TTM | estimate)
Gross
70.4%
EBITDA
-2.2% | 3.5%
EBIT
-9.2%
Net
-47.4% | 0.1%
Free Cash Flow
-5.7%
More
EPS
$-4.3
FCF per Share
$-0.5
Short interest
11.8%
Employees
3k
Rev per Employee
$310.0k
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Myriad Genetics, Inc. forecast:

3x Buy
16%
10x Hold
53%
6x Sell
32%

Analyst Opinions

19 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
16%
Hold
53%
Sell
32%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
833 833
4% 4%
100%
- Direct Costs 247 247
0% 0%
30%
587 587
6% 6%
70%
- Selling and Administrative Expenses 549 549
2% 2%
66%
- Research and Development Expense 114 114
17% 17%
14%
-18 -18
58% 58%
-2%
- Depreciation and Amortization 59 59
2% 2%
7%
EBIT (Operating Income) EBIT -77 -77
25% 25%
-9%
Net Profit -395 -395
154% 154%
-47%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations
Neutral
GlobeNewsWire
14 days ago
Data Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A new nationwide survey from Myriad Genetics shows many women fear cancer screenings—yet most say ge...
Neutral
PRNewsWire
29 days ago
SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (C...
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Samraat Raha
Employees 2,700
Founded 1991
Website myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today